Fanny Calderón
Research Subjects
Research Interests
Fanny Calderón has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Angela L. Riffo-Campos
Universidad de La Frontera, Facultad de Ingeniería y Ciencias, Departamento de Ingeniería Química, Temuco, Chile
1 shared publication - Carlos Manterola
Doctorado en Ciencias Médicas, Universidad de La Frontera, Temuco, Chile
1 shared publication - Elizabeth Guzmán
Comprehensive Medical Services (SERMEDIC), Cuenca 010111, Ecuador
1 shared publication - Enmanuel Isidoro Guerrero Quiroz
Comprehensive Medical Services (SERMEDIC), Cuenca, Ecuador. Faculty of Medicine, Universidad de Cuenca, Ecuador. SOLCA Cancer Institute, Cuenca, Ecuador, Ecuador
1 shared publication - Galo Duque
Faculty of Medicine, Universidad del Azuay, Cuenca 010107, Ecuador
1 shared publication - Josue Rivadeneira
Doctorado en Ciencias Médicas, Universidad de La Frontera, Temuco, Chile
1 shared publication
Latest Publications
- Open Access
- 1 November 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2509
Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer
Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (p < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes.
- 1 November 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2509
Open AccessDifferential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer
Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (p < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes.